Loss to follow-up in registries of rheumatic patients treated with biologics: a potential information bias in assessing pharmacovigilance and efficacy outcomes
Background: The information associated with loss to follow-up (LFU) patients may affect real-world data evaluation of the use of biologics that is not being adequately captured in registries. Methods: We identified all patients (Pts) treated with biologics in our center who had no visits registere...
Main Authors: | Ana Valido, Joana Silva-Dinis, Ana Rita Cruz-Machado, Maria João Gonçalves, Vasco C Romão, Maria João Saavedra, João Eurico Fonseca |
---|---|
Format: | Article |
Language: | English |
Published: |
Sociedade Portuguesa de Reumatologia
2019-10-01
|
Series: | Acta Reumatológica Portuguesa |
Subjects: | |
Online Access: | http://www.actareumatologica.pt/files/article/1278_loss_to_follow_up_in_registries_of_rheumatic_patients_treated_with_biologics_a_potential_information_bias_in_assessing_pharmacovigilance_and_efficacy_outcomes_file.pdf |
Similar Items
-
Major Challenges in Rheumatology: Will We Ever Treat Smarter, Instead of Just Harder?
by: Vasco C. Romão, et al.
Published: (2019-06-01) -
Outcomes of rheumatic patients referred from Portuguese speaking African countries for medical evaluation in Portugal.
by: Vítor Teixeira, et al.
Published: (2019-07-01) -
Efficacy, immunogenicity and cost analysis of a systematic switch from originator infliximab to biosimilar CT-P13 of all patients with inflammatory arthritis from a single center.
by: Ana Valido, et al.
Published: (2019-10-01) -
Switching to Biosimilars in Inflammatory Rheumatic Conditions: Current Knowledge
by: Filipe C. Araújo, et al.
Published: (2018-07-01) -
Pharmacovigilance of Biopharmaceuticals in Rheumatic Diseases, Adverse Events, Evolution, and Perspective: An Overview
by: Sandra Rodríguez, et al.
Published: (2020-08-01)